Oppenheimer Maintains Outperform on Q32 Bio, Raises Price Target to $40

Benzinga · 2d ago
Oppenheimer analyst Jay Olson maintains Q32 Bio (NASDAQ:QTTB) with a Outperform and raises the price target from $20 to $40.